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Distinct Patterns of Autoantibodies
Against G-Protein–Coupled Receptors
in Chagas’ Cardiomyopathy and Megacolon
Their Potential Impact for Early Risk
Assessment in Asymptomatic Chagas’ Patients
Gerd Wallukat, PHD,* Silvia Gilka Muñoz Saravia, MS,†§ Annekathrin Haberland, PHD,‡
Sabine Bartel, PHD,* Raul Araujo, MD,§ Gregorio Valda, MD,§ Diana Duchen, MS,§
Ivan Diaz Ramirez, MD,† Adrian Constantin Borges, MD, PHD,† Ingolf Schimke, PHD†
Berlin, Germany; and Sucre, Bolivia
Objectives Distinguishing the patterns of autoantibodies (AAB) against G-protein–coupled receptors in Chagas’ cardiomyop-
athy and megacolon and the discovery of such a pattern in patients who are as yet asymptomatic could help to
identify patients at high risk of developing the life-threatening complications of Chagas’ disease.
Background Such AAB against receptors as beta 1 (beta1-AAB), beta 2 (beta2-AAB), and muscarinergic 2 (M2-AAB) are
thought to be involved in the pathogenesis of Chagas’ cardiomyopathy and megacolon, the predominant mani-
festations of Chagas’ disease, which is the most serious parasitic disease in Latin America.
Methods Beta1-AAB, beta2-AAB, and M2-AAB were measured in the serum of asymptomatic Chagas’ patients and in
those with cardiomyopathy and/or megacolon.
Results Nearly all Chagas’ patients with cardiomyopathy and/or megacolon had AAB. Predominance of beta1-AAB com-
bined with M2-AAB in Chagas’ cardiomyopathy and beta2-AAB with M2-AAB in megacolon was found. Such pat-
terns were also found in 34% of the asymptomatic patients, of whom 85% possessed a beta1-AAB level typical
for Chagas’ cardiomyopathy.
Conclusions The percentage of asymptomatic Chagas’ patients who had a specific AAB pattern and had a beta1-AAB level
above a defined cutoff point mirrors very well the epidemiological situation, which showed that clinical manifes-
tations develop in nearly 30% of Chagas’ patients and cardiomyopathy in nearly 90% of them. We hypothesize
that beta1-, beta2-, and M2-AAB measurement might be a useful tool for risk assessment in the indeterminate
state of Chagas’ disease to select patients for earlier involvement in care programs. However, prospective stud-
ies are needed to further evaluate this hypothesis. (J Am Coll Cardiol 2010;55:463–8) © 2010 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.06.064e
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phagas’ disease, caused by Trypanosoma cruzi infection, was
ocumented for the year 2006 to affect 15 million patients,
ith an annual incidence and mortality of 40,000 and
2,500 subjects, respectively, making it the most serious
arasitic disease in Latin America (1). Consequently, Cha-
as’ disease places an enormous burden on the countries’
rom the *Max-Delbrück-Centrum Berlin, Berlin, Germany; †Kardiologie-CCM
nd ‡Zentralinstitut für Laboratoriumsmedizin, Charité-Universitätsmedizin Berlin,
erlin, Germany; and the §Santa Ba´rbara Hospital Sucre, Sucre, Bolivia. This study
s supported by Deutsche Gesellschaft für Klinische Chemie und Laboratoriums-
edizin for the Hans-Breuer-Stipendium to Ms. Muñoz Saravia. Dr. Wallukat and
s. Muñoz Saravia contributed equally to this work.a
Manuscript received March 17, 2009; revised manuscript received June 8, 2009,
ccepted June 29, 2009.conomic resources and dramatically affects the patients’
ocial and labor situation (2,3).
Despite being lifelong parasite carriers, two-thirds of the
atients remain in a clinically asymptomatic (indeterminate)
tate, whereas clinical manifestations develop in one-third,
ith a latency of 10 to 30 years. In nearly 90% of these cases,
he patient’s heart is affected and the patient presents with
ardiomyopathy associated with arrhythmias, heart failure,
nd frequently sudden death. The remaining 10% have
astrointestinal disorders, mainly megacolon or megaesoph-
gus (4–6). Unfortunately, there is no tool available for
dentification of patients who possess a high risk for
rogressing from the indeterminate state into the state
ssociated with the life-threatening complications.
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Autoantibody Pattern in Chagas’ Cardiomyopathy February 2, 2010:463–8After the discovery of autoanti-
bodies (AAB) against G-protein–
coupled receptors in Chagas’ car-
diomyopathy and megacolon, such
as those against the beta 1- and
beta 2-adrenergic receptor (beta1-
AAB, beta2-AAB) and the mus-
carinergic 2 receptor (M2-AAB),
which suggests an autoimmune
etiology (7,8), we hypothesize
that such AAB could possess the
potential for risk assessment in
asymptomatic Chagas’ patients.
Therefore, we looked for specific
AAB patterns that occur in the
ifferent organ manifestations and afterward for the occur-
ence of such patterns in asymptomatic patients.
ethods
tudy participants. The retrospective study was approved
y the authorities of the Santa Ba´rbara Hospital, Sucre,
olivia. All patients signed an informed consent form.
erum was taken from 29 healthy controls (C) and, between
uly 2006 and August 2007, consecutively from 228 patients
ith Chagas’ disease. Patients were indicated by positivity
or antibodies against Trypanosoma cruzi detected by
nzyme-linked immunosorbent assay (Wiener Laboratorios
.A.I.C., Rosario, Santa Fe, Argentina) and indirect hem-
gglutination (Polychaco S.A.I.C., Buenos Aires, Argen-
ina). Patients were admitted to the cardiological and
astroenterological departments, and there they were clas-
ified by clinical investigation, electrocardiographic map-
ing, and radiological imaging as being in the indeterminate
tate (I group) or as having cardiomyopathy (CM group),
egacolon only (MC group), or both cardiomyopathy and
Basic Patient Data and ChronotropicAutoantibody Positivity in Chr nic Chagas’ DiseTable 1 Basic P ient Data and ChronotropiAutoantibody Positivity in Chronic C
C
n (male/female) 29 (9/20)
Age (yrs), median (min/max) 30 (19/61)
AAB positivity (%)
Beta1-AAB 0
Beta2-AAB 3
M2-AAB 0
Beta1-/M2-AAB 0
Beta2-/M2-AAB 0
Beta1-/M2-AAB or beta2-/M2-AAB 0
Categories of cardiomyopathy (%)
Mild
Moderate
Severe
Basic data and percentages of positivity for autoantibodies (AAB) ag
(beta1-AAB, beta2-AAB, M2-AAB) of the 228 Chagas’ patients and 29
C  healthy control subjects; CM  patients with chronic Chagas
Abbreviations
and Acronyms
AAB  autoantibodies
beta1-AAB 
autoantibodies against
beta1-adrenergic receptor
beta2-AAB 
autoantibodies against
beta2-adrenergic receptor
M2-AAB  autoantibodies
against muscarinergic 2
receptor
PBS  phosphate-buffered
salineChagas’ disease manifested as cardiomyopathy combined with megacolon; I
state; MC  patients with chronic Chagas’ disease manifested as megacolonegacolon (CMMC group). Patients with cardiomyopa-
hy (CM and CMMC groups) were subdivided by 3
ardiologists independently of each other based on electro-
ardiographic and radiological imaging into mild, moderate,
nd severe categories. The presence of at least 1 of the
ollowing criteria was used to classify the cardiomyopathy;
ild: mild electrocardiographic changes in ventricular
epolarization, sinus bradycardia; moderate: left anterior
ascicular block, incomplete left bundle branch block,
ight bundle branch block, second-degree atrioventricular
lock Mobitz type I, atrial fibrillation in patients age 50
ears; and severe: cardiomegaly, dilatative cardiomyopa-
hy, complete left bundle branch block, atrioventricular
lock Mobitz type II, complete atrioventricular block,
trial fibrillation in patients age 50 years. The patients’
asic characteristics are shown in Table 1.
For identification and quantification of the AAB, a
ioassay was used that was first established for measurement
f AAB against G-protein–coupled receptors by Wallukat
nd Wollenberger (9), and is briefly described here. In this
ioassay, the chronotropic response of spontaneously beat-
ng cultured neonatal rat cardiomyocytes was recorded,
hich is the sum of positive chronotropy by beta1- and
eta2-AAB and negative chronotropy by M2-AAB (1 U of
AB activity  1 beat/min frequency change).
To differentiate the AAB species with respect to their
ontribution to the chronotropic response, analysis was
onducted in the presence of specific antagonists such as
CI-118.551 for beta2-AAB, atropine for M2-AAB, and
ropranolol for beta1-/beta2-AAB. The AAB positivity
as defined using cutoff values that were calculated based on
 3 SD of the AAB levels of more than 100 healthy
ubjects found in previous studies. For the positive chrono-
ropic response of cultured neonatal rat cardiomyocytes
o beta1- and beta2-AAB, a cutoff 4.0 U and for the
s’ Disease
I CM MC CMMC
6/70) 57 (34/23) 30 (11/19) 45 (21/24)
8/82) 47 (18/82) 46 (19/78) 54 (29/81)
4 100* 38 96
3 89 97 98
2 98 100 100
9 98 38 96
4 89 97 98
4 98 99 96
5 15
44 56
51 29
eta 1-adrenergic, beta 2-adrenergic, and muscarinergic 2 receptors
y subjects. *CM  MC, p  0.001.
e manifested as cardiomyopathy; CMMC  patients with chronicasec
haga
96 (2
30 (1
3
3
4
2
2
3
ainst b
health
’ diseaspatients with Chagas’ disease in the indeterminate (asymptomatic)
only.
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February 2, 2010:463–8 Autoantibody Pattern in Chagas’ Cardiomyopathyegative response to M2-AAB a cutoff 4.0 U was
alculated.
ardiomyocyte preparation and culturing. Hearts of 1-
o 3-day-old rats were removed under sterile conditions and
ransferred to phosphate-buffered saline (PBS) solution
ontaining penicillin/streptomycin. The ventricle tissue was
eparated, dissected in pieces, and washed twice with 10 ml
BS containing penicillin/streptomycin and at last once
ith PBS only. The ventricle pieces were suspended in 30
l PBS containing 0.2% trypsin. After incubation for 20
in at 37°C, the trypsinization was stopped with 10 ml
ce-cold heat-inactivated calf serum. The resulting suspen-
ion was centrifuged at 130 g for 6 min, and the pellet was
ransferred to 20 ml SM20-I medium. For cell count
stimation, 100 l of this suspension was added to 100 l
rypan blue solution. For cell culturing 2.4  106 cells were
uspended in 2.5 ml of glucose containing SM20-I medium,
hich was equilibrated with humid air and supplemented
ith 10% heat-inactivated calf serum, 0.1 mU insulin, and
M fluorodeoxyuridine (for prevention of overgrowth of
he myocytes by nonmyocytes), transferred to 12.5-cm2
alcon flasks, and cultured as monolayer for 4 days at 37°C.
he medium was renewed after 2 days.
ssay standardization. On the fourth day, the medium
as removed and replaced by 2 ml of SM20-I containing
0% heat-inactivated calf serum and incubated at 37°C for
h. After the incubation, the flasks were transferred onto a
eated stage (37°C) of an inverted microscope where 8
ynchronously beating fields of the cell layer were marked.
he number of beats of each field was counted for 15 s and
veraged with computer assistance using the Modular Im-
ge Analyzing System Imagequant-Fourier Analysis version
.1 (Mediquant GmbH, Lützen, Germany). To use the
ioassay for the estimation of the AAB activities, the
ollowing criteria must be fulfilled: 1) the basal beating rate
ust range between 120 and 160 beats/min; 2) cells
timulated for 5 min with isoprenaline (10 M) as positive
ontrol must respond with a frequency increase of more
han 45 to 50 beats/min; and 3) because in patients with
hagas’ disease beta1-, beta2-, and M2-AAB recognize
pitopes on the second extracellular loops of the receptors
nd the antibodies were neutralized using peptides corre-
ponding to these loops, cells must respond to a further
ositive control, a commercial polyclonal antibody against
he second extracellular loop of the beta1-adrenergic recep-
or (Goat anti-ADRB1, EB07133, Everest Biotech Ltd.,
xfordshire, United Kingdom). After incubation of the
ells for 1 h with the commercial autoantibody in a dilution
f 1:100, the beating frequency must increase by 20
eats/min and its chronotropic effects must be strongly
locked by propranolol antagonizing both beta1- and
eta2-AAB and by bisoprolol specifically antagonizing
he beta1-AAB. If the bioassay fulfills these criteria, the
ifferences between the basal beating rate and the rate
fter the addition of the agonist and/or the autoantibod-
es (delta beating rate) is very similar from day to day even wf the basal pulsating rate differs. Therefore, the delta
eating rate is used to express the stimulating and
epressing activity of sera containing beta1-, beta2-, and
2-AAB, respectively. For the delta beating rate in the
resence of isoprenaline and the commercial beta1-AAB,
day-to-day variation of 15% was estimated.
AB measurement and differentiation. SAMPLE PREPA-
ATION. One milliliter of control and patient serum and
60 l saturated ammonium sulfate solution were mixed
final concentration 40% ammonium sulfate) and incu-
ated for 18 h at 4°C. After centrifugation for 15 min at
,000 g, the pellet was resuspended in 750 l PBS, mixed
ith 750 l saturated ammonium sulfate solution (final
oncentration 50% ammonium sulfate), and centrifuged
gain. After this, the pellet was suspended in 700 l PBS
nd dialyzed against the 100-fold volume of PBS. The
esulting immunoglobulin G fraction can be stored at
20°C.
EASUREMENT AND DIFFERENTIATION. In cell cultures
repared and cultured as described earlier, the basal
eating rate of 8 fields of the cell layer was counted. The
ddition of atropine (final concentration 10 M) served
s the inhibition of the M2 receptors of the cells,
xcluding negative chronotropic interferences and en-
bling the measurement of the positive chronotropic
ctivity of the patient AAB preparation. For this purpose,
atient immunoglobulin G was added (dilution 1:20) to
he assay medium and incubated for 1 h. Then the
eating rate of the same fields as used for the estimation
f the basal rate was counted to calculate the delta
eating rate, which represents the sum of the beta1- and
eta2-AAB activity. To separate the beta1- from the
eta2-AAB activity, the beating rate was counted in the
resence of the specific beta2-antagonist ICI-118.551
0.1 M).
The M2-AAB activity was measured in a separate exper-
ment. After recording the basal beating frequency, 1 M
ropranolol was added, which antagonizes beta1- and
eta2-AAB. Therefore, all interferences caused by positive
hronotropic AAB can be excluded. Patients’ M2-AAB
ctivity (negative chronotropic) was calculated by measuring
he decrease of the beating frequency.
tatistical analysis. Patient age is presented as median,
aximum, and minimum. The AAB levels are expressed
s a box plot showing a median bar, 25th and 75th
ercentiles (interquartile range), whiskers with ends that
epresent the largest and smallest values inside the 1.5
nterquartile range, and outliers (open circles) defined as
value between the 1.5 and 3 interquartile range.
tatistical analysis was performed using the SPSS soft-
are package (SPSS Inc., Chicago, Illinois). Correlations
ere checked by determination of the Spearman correla-
ion coefficient. For dichotomous data, the chi-square
nd Fisher exact test were used. Intergroup comparison
as analyzed by the Kruskal-Wallis H-test and as a
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Autoantibody Pattern in Chagas’ Cardiomyopathy February 2, 2010:463–8ost-hoc analysis by the Mann-Whitney U test without
orrection for the multiple comparison.
esults
s shown in Table 1, control subjects and patients in the
ndeterminate state were younger than the patients with
ardiomyopathy and megacolon. However, no correlation
xisted between patient age and AAB positivity or AAB
evels.
In the control group, beta1- and M2-AAB were absent in
00% of the subjects, but 1 subject (3%) had beta2-AAB.
hagas’ patients with cardiomyopathy were positive to
00% for beta1-AAB, to 89% for beta2-AAB, and to 98%
or M2-AAB. In contrast, Chagas’ patients with megacolon
ere positive to 97% for beta2-AAB and to 100% for
2-AAB, but only to 38% for beta1-AAB, which is
ignificantly lower than in the cardiomyopathy patients.
atients with both diseases possessed all 3 AABs to nearly
00%. In consequence, Chagas’ cardiomyopathy or mega-
olon patients are always detected by 1 or both of the
utoantibody combinations beta1-/M2-AAB and beta2-/
2-AAB.
In the indeterminate state, 34%, 33%, and 42% of the
atients were positive for beta1-, beta2-, and M2-AAB,
espectively. With respect to the AAB compositions, 34% of
he asymptomatic patients were positive either for beta1-/ or
MCCM/CM+MCI
A
A
B
 A
ct
iv
it
y 
(U
)
30
15
0
-15
-30
Positive Chronotropy
(†)
(‡)
(§)
(*)
Negative Chronotropy
Figure 1 Activity of Chronotropic
Autoantibodies in Chronic Chagas’ Disease
Activities (1 unit  1 beat/min frequency change) of autobodies against beta
1-adrenergic, beta 2-adrenergic, and muscarinergic 2 receptors (beta1-AAB,
beta2-AAB, M2-AAB) in patients with chronic Chagas’ disease who were posi-
tive for the AAB combinations beta1-/M2-AAB or beta2-/M2-AAB or both AAB
combinations and who were in the indeterminate state (I) or with cardiomyopa-
thy (CM/CMMC) or megacolon exclusively (MC). Box plots with median bars,
25th and 75th percentiles, whiskers, and outliers (open circles) are shown.
Red boxes  beta1-AAB; green boxes  beta2-AAB; blue boxes  M2-AAB.
*p  0.001 I  MC. †p  0.001 CM/CMMC  MC. ‡p  0.05 MC 
CM/CMMC. §p  0.01 CM/CMMC  MC.eta2-/M2-AAB or even for both AAB combinations.Comparing the AAB levels of the patients in the inde-
erminate state or having cardiomyopathy (groups CM and
MMC) or megacolon only and who were positive for
he AAB combinations beta1-/ or beta2-/M2-AAB, beta1-
nd M2-AAB were significantly higher in patients with
ardiomyopathy than in the megacolon patients. In contrast,
eta2-AAB was highest in the patients with megacolon
nly. The patients in the indeterminate state had higher
eta1- and M2-AAB levels than the megacolon patients.
o significant differences in the AAB levels were seen in the
atients in the indeterminate state and those with cardio-
yopathy (Fig. 1).
To find out which AAB level best distinguished between
atients with cardiomyopathy and those with megacolon,
e constructed the receiver-operator characteristic curve.
or the beta1-AAB curve, all patients with cardiomyopathy
groups CM and CMMC) versus those with megacolon
nly were included in the analysis. The cutoff of 8.9 U for
eta1-AAB (sensitivity 0.94, specificity 0.85, positive pre-
ictive value 0.96, and negative predictive value 0.82) was
ound to be the best to distinguish between patients with
ardiomyopathy and those with megacolon (Fig. 2).
Next we used this cutoff to determinate the percentage of
atients in the indeterminate state who presented with the
ardiomyopathy- and megacolon-specific level. In the inde-
erminate patients positive for the AAB combinations
eta1-/M2-AAB, beta2-/M2-AAB, or both combinations,
he cardiomyopathy-specific beta1-AAB level 8.9 U was
ound in 90% of the patients, whereas 10% showed a level
haracteristic for megacolon.
Additionally, we show in Figure 3 an increase in the
eta1-AAB level from patients in the indeterminate state
hought to have risk for cardiomyopathy (beta1-/M2-AAB
ositivity, beta1-AAB level 8.9 U) to patients with mild
1 - Specificity
1.00.80.60.40.20.0
S
en
si
ti
vi
ty
1.0
0.8
0.6
0.4
0.2
0.0
Anmerkung  Cut off         8.9 U
Sensitivity    0.94
Specificity    0.85
PPV             0.96
NPV             0.82
Figure 2 ROC Curve for Beta1-AAB Activity in
Symptomatic Chronic Chagas’ Disease
Receiver-operating characteristics (ROC) based on the beta1-adrenergic autoan-
tibody levels of chronic Chagas’ patients with either cardiomyopathy (CM/
CMMC) or exclusively megacolon (MC). NPV  negative predictive value;
PPV  positive predictive value; other abbreviations as in Figure 1.
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February 2, 2010:463–8 Autoantibody Pattern in Chagas’ Cardiomyopathyr moderate cardiomyopathy to patients with severe cardio-
yopathy (Fig. 3).
iscussion
e found that nearly all chronic Chagas’ patients with
ardiomyopathy and/or megacolon had AAB against G-
rotein–coupled receptors such as beta1-, beta2-, and M2-
AB, which agrees with recently published findings (10–12).
dditionally, we showed specifically composed patterns of
eta1-, beta2-, and M2-AAB in chronic Chagas’ patients.
An AAB pattern frequently composed of beta1-, beta2-,
nd M2-AAB was indicative for Chagas’ cardiomyopathy.
egacolon patients had beta2- and M2-AAB, but with
ower frequency beta1-AAB. Aside from the distinguished
omposition of the AAB pattern in Chagas’ cardiomyopa-
hy and megacolon, we also showed different levels of the
AB that were higher for beta1- and M2-AAB in cardio-
yopathy and for beta2-AAB in megacolon. Based on
eceiver-operator characteristic analysis, a cutoff of 8.9 U for
eta1-AAB is the best way to distinguish between patients
ith cardiomyopathy and those with megacolon. We then
howed that nearly one-third of the asymptomatic patients,
hus those being in the indeterminate state, already carried
AB. Interestingly, the frequency of AAB positivity in the
ndeterminate state parallels the epidemiological situation
hat nearly 30% of infected subjects develop clinical mani-
estations (4–7).
Additionally, the frequency of 90% of the AAB-positive pa-
Cardiomyopathy
SevereMild/ModerateRisk
b
et
a1
-A
A
B
 A
ct
iv
it
y 
(U
)
30
20
10
0
(†)
(*)
Figure 3 Beta1-AAB Activity in Chagas’ Cardiomyopathy
Activities (1 unit  1 beat/min frequency change) of beta1-AAB in Chagas’
patients with the risk for cardiomyopathy (patients of the indeterminate state
indicated by the AAB composition: beta1/M2-AAB positivity and beta1-AAB level
8.9 U) and with manifested cardiomyopathy (CM/CMMC) subdivided based
on electrocardiographic and radiological imaging into mild/moderate and
severe cardiomyopathy. Box plots with median bars, 25th and 75th percen-
tiles, and whiskers, are shown. *p  0.1 mild/moderate cardiomyopathy 
cardiomyopathy risk. †p  0.02 severe cardiomyopathy  cardiomyopathy risk.
Abbreviations as in Figure 1.ients in the indeterminate state who showed a cardiomyopathy-ypical beta1-AAB level, whereas 10% showed the megacolon
evel, again mirrors the epidemiological data for patients
oving from the indeterminate state to Chagas’ cardiomyop-
thy and megacolon, respectively (4–7). All of these findings
or AAB in chronic Chagas’ patients manifest in our view the
ypothesis of AAB as a pathogenic driver for clinical manifes-
ations such as cardiomyopathy and megacolon in Chagas’
isease. The first-time demonstration of relationships between
he beta1-AAB and partially of the M2-AAB level and the
everity of cardiomyopathy also supports the pathogenic func-
ion of AAB against G-protein–coupled receptors in chronic
hagas’ disease, which has already been deduced from exper-
ments showing potentially pathogenic interactions of AAB
solated from Chagas’ patients with cells and specimens ob-
ained from animals and humans (8,13–16). Most impressive
n this context is, due to the cross-talk between beta1-AAB
f Chagas’ patients and patients with idiopathic dilated
ardiomyopathy (17), the induction of cardiomyopathy in
ats after the transfer of idiopathic dilated cardiomyopathy
eta1-AAB (18).
Furthermore, the concordance between the epidemiolog-
cal data for heart and gastrointestinal disease in Chagas’
atients and the frequency of asymptomatic patients carry-
ng typical cardiomyopathy or megacolon AAB patterns for
he first time offer an indication that measurement of AAB
n asymptomatic Chagas’ patients could be helpful in
nding those indeterminate patients who have a high risk of
eveloping the life-threatening complication of Chagas’
isease. This would allow earlier patient enrollment in care
rograms to prevent or delay the clinical manifestations in
hagas’ disease. However, our suggestion of using AAB
gainst G-protein–coupled receptors as risk markers in
hagas’ patients is preliminary and needs prospective stud-
es for substantiation.
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